HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal cell carcinoma in China met its primary endpoint of progression-free survival (PFS).
Іn addition to the primary endpoint, the combination therapy also demonstrated improvements in secondary endpoints including objective response rate and duration of response.
Complete results will be presented at an upcoming conference, according to a Wednesday filing with the Hong Kong bourse.
The combo therapy also secured conditional approval for treating advanced endometrial cancer from China's National Medical Products Association.
Hutchmed's shares were up by 4%, while those of Innovent were down 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。